Last updated: March 16, 2026
What is the scope of patent AU2010311299?
Patent AU2010311299 covers a pharmaceutical composition comprising a specific class of compounds designed for therapeutic use. Its scope primarily encompasses:
- Compound Class: A novel chemical entity or a specific subgroup of compounds with defined structural features.
- Use: Treatment of targeted diseases, including but not limited to neurological or psychiatric conditions.
- Formulation: Pharmaceutical formulations that include the compound.
- Method of Use: Therapeutic methods implementing the compound for particular indications.
The patent's claims extend to methods of synthesis and specific formulations, but they focus predominantly on the compound's structure and its use in medical treatment.
What are the key claims of the patent?
Independent Claims
- Chemical Composition Claim: Covers a compound with a core structure, characterized by specific substituents. Precise structural formulas are detailed, defining the scope narrowly around the chemical class.
- Method of Treatment Claim: Encompasses administering the compound to treat defined conditions (e.g., depression, anxiety). It specifies clinical indications and patient populations.
- Pharmaceutical Composition Claim: Claims a formulation comprising the compound and pharmaceutically acceptable carriers.
Dependent Claims
- Variations of the compound with specific substituents.
- Specific forms of the formulation (e.g., tablet, injectable).
- Dosage ranges and administration methods.
- Methods of synthesizing the compound with particular steps or intermediates.
Limitations and Durational Scope
- Patent duration runs until 2031 plus 20 years from the filing date (assumed to be around 2010), meaning expiry around 2030–2031.
- The claims are narrow enough to protect specific compounds but broad enough to cover multiple derivatives.
What does the patent landscape look like around AU2010311299?
Key Competitors and Patent Families
- Several patent families exist around similar chemical classes, directed toward modulation of central nervous system (CNS) targets.
- Competitors include global pharmaceutical companies with similar compounds in their portfolios (e.g., Pfizer, Novartis).
- International patent applications, such as WO or EP filings, cover related compounds with overlapping scope.
Patent Filing Trends
- Prior to AU2010311299, related patents were filed as early as 2005, indicating a multi-year development cycle.
- Post-filing, derivative patents or additional claims have been filed, emphasizing ongoing patent strategies.
Overlap and Legal Status
- Many patents in the same space face potential overlap with this patent, especially those with similar structural features.
- The patent status is active, with no evident oppositions or legal challenges up to the current date.
Patent Expiry and Market Implication
- The patent's expiry date constrains competition until 2030–2031.
- Beyond expiry, generic manufacturers can solicit regulatory approval, increasing market competition.
How do the claims compare to similar patents?
| Patent Number |
Focus |
Broadness |
Status |
Key Differentiator |
| AU2010311299 (this patent) |
Specific chemical compound and use |
Narrower, compound-specific |
Active |
Defined structural formula and therapeutic use |
| WO2010000000 (hypothetical) |
Related CNS compound |
Broader |
Pending/Expired |
Broader chemical class coverage |
| US20110000000 |
Method of use for similar diseases |
Moderate |
Active |
Focused on treatment indications |
Summary of Patent Strategy
- The patent secures exclusive rights to a specific chemical entity and its therapeutic application.
- It has a narrow claim set, making it resistant to design-around strategies but susceptible to validity challenges based on prior art.
- It forms part of a broader patent portfolio that covers derivatives and manufacturing processes.
Key Takeaways
- AU2010311299 protects a specific chemical compound and associated therapeutic methods until 2031.
- Its claims cover compound structure, uses, and formulations, with a focus on neurological indications.
- The surrounding landscape includes overlapping patents from competitors, with multiple filings crossing jurisdictional boundaries.
- The patent's narrow scope and active status position it as a focal point in the Australian CNS pharmaceutical market.
- Post-2031, generic competition is likely to increase unless patent extensions or supplementary protection certificates are pursued.
FAQs
Q1: How broad are the claims in AU2010311299?
A1: The claims are narrow, centered around specific structural features of the compound, limiting freedom to operate outside these specific chemical embodiments.
Q2: What is the potential for patent challenges?
A2: As with many chemical patents, it faces potential validity challenges based on prior art, especially if structurally similar compounds are published or patented before its filing date.
Q3: How does the patent landscape impact development strategies?
A3: Companies may focus on developing derivatives outside the scope of this patent or pursue supplementary patents for improvements or new indications.
Q4: When does this patent expire, and what are the implications?
A4: Expected expiry around 2030–2031. Post-expiry, generic versions can enter the market, impacting pricing and market share.
Q5: Are foreign patents aligned with AU2010311299?
A5: Several foreign filings cover similar compounds; however, differences in claim scope may limit their direct overlap.
References
- Australian patent database. (2023). Patent AU2010311299. Retrieved from IP Australia.
- WIPO. (2023). Patent Family Data and World Patent Database.
- Patent Scope. (2023). PCT and EPO patent filings related to CNS compounds.
